Equities

Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc

Actions
  • Price (EUR)1.26
  • Today's Change-0.04 / -3.08%
  • Shares traded1.30k
  • 1 Year change0.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments5.261310
Total Receivables, Net242214
Total Inventory312321
Prepaid expenses10122.06
Other current assets, total2.302.301.28
Total current assets727349
Property, plant & equipment, net0.780.901.22
Goodwill, net101011
Intangibles, net647077
Long term investments------
Note receivable - long term------
Other long term assets--01.64
Total assets156161139
LIABILITIES
Accounts payable7.751012
Accrued expenses352317
Notes payable/short-term debt000
Current portion long-term debt/capital leases164315
Other current liabilities, total7.257.383.89
Total current liabilities668348
Total long term debt342740
Total debt507055
Deferred income tax--01.52
Minority interest------
Other liabilities, total252832
Total liabilities125139121
SHAREHOLDERS EQUITY
Common stock766969
Additional paid-in capital121110
Retained earnings (accumulated deficit)(64)(64)(65)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total6.176.163.97
Total equity302218
Total liabilities & shareholders' equity156161139
Total common shares outstanding242020
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.